Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 17

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 17
---
 outstanding immediately prior to the Effective Time (other than a Common Share held by a                                                                                                                                        
 Dissenting Shareholder in respect of which Dissent Rights have been validly exercised under the Plan of Arrangement, the Purchaser or any affiliate of the Purchaser) shall be deemed to be assigned and transferred by the holder thereof to the 
 Purchaser in exchange for the Cash Amount plus the issuance by the Purchaser of one CVR per Common Share, and:                                                                                                                                    |

| (i) | each registered holder of such Common Shares shall cease to be the registered holder thereof and to have any 
 rights as a Shareholder other than the right to be paid one CVR per Common Share;                            |

| (ii) | the name of each such registered holder shall be removed from the register of the Shareholders maintained by or 
 on behalf of the Company;                                                                                       |

3

| (iii) | the Purchaser shall be deemed to be the transferee of such Common Shares free and clear of all Encumbrances and 
 shall be entered in the register of the Shareholders maintained by or on behalf of the Company; and             |

| h) | the exchanges and cancellations provided for in this Section 2.3 will be deemed to occur on the Effective              
 Date, notwithstanding that certain of the procedures related thereto are not completed until after the Effective Date. |

Following completion of the Arrangement, the Company will apply to cease to be a reporting issuer in Canada and the Common Shares will be delisted from Nasdaq Global Select Market (“ Nasdaq”) and deregistered under the U.S. Securities Exchange Act of 1934, as amended (the “ Exchange Act”), in each case, in accordance with applicable Laws, rules and regulations. Following completion of the Arrangement and such deregistration, the Company will no longer file periodic reports with the U.S. Securities and Exchange Commission (the “ SEC”). The Arrangement will be carried out pursuant to the terms of the Agreement and the Plan of Arrangement. Arrangement Consideration Pursuant to the Agreement, the Purchaser will, among other things, acquire all of the issued and outstanding Common Shares and Shareholders will receive (a) a cash payment per Common Share (the “ Cash Amount”), which is currently estimated to be approximately US$1.82 per Common Share and which will be finally determined based upon the Company’s cash balance immediately prior to the closing of the Transaction (the “ Closing”) after deducting certain transaction costs, the aggregate amount of outstanding liabilities